Table 1.
Summary of data sources
| Site A | Site B | Site C | Site D | Site E | Site F | Site G | Total | |
|---|---|---|---|---|---|---|---|---|
| SUPPORT-HF2 staff interviews | 11: consultant cardiologist/CI, trial manager, lead research nurse, 6 community HFSNs, bio-engineer, GP | 3: consultant cardiologist/PI, 2 research nurses | 4: research nurse, 3 HFSNs (1 hospital, 2 communities) | 1: research practitioner | 2: consultant cardiologist/PI, research administrator | 1: hospital HFSN | 1: consultant cardiologist/CI | 23 |
| SUPPORT-HF2 patient interviews | 4 (including 1 spouse) | 5 (including 1 spouse) | 4 | 3 | 0 | 5 | 21 | |
| SUPPORT-HF2 patient discussion group | 7 (6 patients, 1 spouse) | 7 | ||||||
| Documents |
SUPPORT-HF2 study protocol Minutes of 5 meetings during the study set-up phase Minutes of a significant event review meeting (exploring the relationship between SUPPORT-HF2-driven drug up-titration and subsequent hospital admission) Approximately 50 email exchanges between site staff and researchers Approximately 10 emails between lead study nurse and researchers |
Approx. 110 pages | ||||||
| Total | Directly involved in the trial: 25 patients, 3 spouses, 4 consultant cardiologists who were also local principal investigators, 10 heart failure specialist nurses, 4 research nurses, 1 trial manager, 1 bioengineer, 1 research practitioner, 1 research administrator | 51 people | ||||||